Establishing Core Symptoms of Acute Serotonin Reuptake Inhibitor Withdrawal: Results from an International Survey of Online Peer-Support Communities

Abstract

Background Serotonin reuptake inhibitor (SRI) antidepressants are commonly associated with withdrawal reactions. The Discontinuation Emergent Signs and Symptoms (DESS) checklist has been considered the gold standard research and screening tool for SRI withdrawal but has several limitations, including its length, lack of specificity, and omission of baseline symptom and symptom severity scores, making it impractical for use in clinical or research settings. We investigated the prevalence and severity of common SRI withdrawal symptoms to determine whether a very small subset of symptoms can capture most occurrences of SRI withdrawal.

Methods We surveyed 344 members of online peer-support communities aged 18–65, reporting withdrawal symptoms after chronic SRI treatment. The severity of nine common withdrawal symptoms was evaluated at baseline and during the withdrawal period.

Results Dizziness, brain zaps, irritability/agitation, and anxiety/nervousness demonstrated the largest increase in severity during withdrawal relative to baseline. Nearly all (97.7%) of the 344 subjects and all (100%) 153 subjects with relatively low baseline symptom scores (total<5) reported a worsening of one of these four symptoms. The presence of a baseline anxiety disorder did not affect rates of withdrawal-emergent anxiety/nervousness.

Conclusion Nearly all surveyed subjects reported worsening either of dizziness, brain zaps, irritability/agitation, or anxiety/nervousness in acute withdrawal. A screening test incorporating these four core symptoms may be sufficiently sensitive to rule out SRI withdrawal and may be valuable in clinical and research settings. Incorporating withdrawal symptom severity may further enhance specificity.

Key words

selective serotonin reuptake inhibitors (ssris) - serotonin - mood disorders - discontinuation of drugs

Publikationsverlauf

Eingereicht: 21. November 2022
Eingereicht: 13. April 2023

Angenommen: 10. April 2023

Artikel online veröffentlicht:
30. Mai 2023

• References

• 1 Haddad P.. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997; 58: 17-22
• 2 Wilson E, Lader M.. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357-68
• 3 Taylor D, Stewart S, Connolly A.. Antidepressant withdrawal symptoms – telephone calls to a national medication helpline. J Affect Disord 2006; 95: 129-33
• 4 Rosenbaum JF, Fava M, Hoog SL. et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998; 44: 77-87
• 5 Lader M.. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007; 67: 1657-1663
• 6 Siwek M, Chrobak AA, Gorostowicz A. et al. Withdrawal symptoms following discontinuation of vortioxetine – retrospective chart review. Pharmaceuticals 2021; 14: 451
• 7 Davies J, Read J.. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?. Addict Behav 2019; 97: 111-121
• 8 Kaufman MJ, Henry ME, Frederick Bd. et al. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: A proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 2003; 54: 534-539
• 9 Lewis G, Marston L, Duffy L. et al. Maintenance or discontinuation of antidepressants in primary care. New Engl J of Med 2021; 385: 1257-1267
• 10 Fava M.. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006; 67: 14
• 11 Guy A, Brown M, Lewis S. et al. The ‘patient voice’: Patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Ther Adv in Psychopharmacol 2020; 10: 2045125320967183
• 12 Read J, Renton J, Harrop C. et al. A survey of UK general practitioners about depression, antidepressants and withdrawal: Implementing the 2019 Public Health England report. Ther Adv Psychopharmacol 2020; 10: 2045125320950124
• 13 Framer A.. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Ther Adv in Psychopharmacol 2021; 11: 2045125321991274
• 14 Rosenbaum JF, Fava M, Hoog SL. et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998; 44: 77-87
• 15 Horowitz MA, Taylor D.. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiat 2019; 6: 538-546
• 16 Papp A, Onton JA.. Triggers and characteristics of brain zaps according to the findings of an internet questionnaire. Prim Care Companion CNS Disord 2022; 24: 39597
• 17 Read J.. How common and severe are six withdrawal effects from, and addiction to, antidepressants? The experiences of a large international sample of patients. Addict Behav 2020; 102: 106157
• 18 Kroenke K, Spitzer RL, Williams JB.. The Patient Health Questionnaire-2: Validity of a two-item depression screener. Med Care 2003; 1284-1292
• 19 Manea L, Gilbody S, Hewitt C. et al. Identifying depression with the PHQ-2: A diagnostic meta-analysis. J Affect Disord 2016; 203: 382-395
• 20 Horowitz MA, Taylor D.. Distinguishing relapse from antidepressant withdrawal: Clinical practice and antidepressant discontinuation studies. BJPsych Adv 2022; 28: 297-311
• 21 Hengartner MP, Davies J, Read J.. Antidepressant withdrawal–the tide is finally turning. Epidemiol Psychiatr. Sci 2020; 29
• 22 Davies J, Read J, Hengartner MP. et al. Clinical guidelines on antidepressant withdrawal urgently need updating. Br Med J 2019; 365
• 23 Cosci F, Chouinard G.. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020; 89: 283-306